Why the study?
What are the rates and disparities in the early uptake of GLP1-RA and SGLT2i among Medicare-insured older adults with T2D and newly diagnosed ASCVD or CHF?
What are the rates and disparities in the early uptake of GLP1-RA and SGLT2i among Medicare-insured older adults with T2D and newly diagnosed ASCVD or CHF?
There is a substantial deficit and significant racial and socioeconomic disparities in the delivery of guideline-recommended GLP1-RA and SGLT2i therapies among Medicare beneficiaries with T2D and incident ASCVD or CHF.
Low uptake with racial/socioeconomic disparities signals care gaps; leaves open whether targeted interventions improve equitable GLP1-RA/SGLT2i access.
Among older adults with T2D and either ASCVD or CHF, initiation of GLP1-RA or SGLT2i was low, suggesting a substantial deficit in delivery of guideline-recommended care or treatment barriers. Individuals of Black and other race/ethnicity and those with higher area-level socioeconomic deprivation were less likely to initiate these medications.
No takes yet. Share an insight, caveat, or question.
Cromer et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: